Treating Acute Pancreatitis With Dabigatran, a Pilot Study

• Status: Recruiting
• Trial end date: 2022-08-30
• Target enrollment: 0
• Participant gender: All

Summary

Researchers are studying the safety and efficacy of Dabigatran in the treatment of acute pancreatitis.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Dabigatran

Criteria

Inclusion Criteria:

• Acute Pancreatitis (presence at least two of three features: typical pain, amylase or lipase >3 times UNL and AP on images)

• 18-75 years old

• Willingness to sign the informed consent

• Symptom onset within 72 hours

Exclusion Criteria:

• Under 18 years of age or over 75 years of age

• Pregnancy or lactating

• Presence of pseudo aneurysm on CT

• Predicted severe acute pancreatitis

• Unwilling or unable to sign the informed consent

• Had recent surgery or sphincterotomy

• Active pathological bleeding

• Concurrent use of anti-coagulation

• Known serious hypersensitivity reaction to Dabigatran

• CrCI <30mL/min or on dialysis

• Mechanical prosthetic valves

• Liver disease

• Cancer

• On Chemotherapy or immunosuppressant

• Persistent ALT, AST, Akl Phos >2 x ULN

• Active hepatitis C, active hepatitis B, and active hepatitis A

• Anemia (hemoglobin <10g/dL)

• Thrombocytopenia

• Concomitant use of P-gp inhibitors